Verified factor-similar pair

VIOV vs VTWV

These two ETFs meet the same FF6 US comparison criteria: US-listed equity ETFs, the same USD model basis, at least one material non-market factor, and 100% overlap in statistically significant material factor exposure.

SMB HML
Similarity score
91
Near substitute

The score combines exposure-level distance, factor-vector shape, market-beta closeness, and a small backtested relative-Sharpe term.

Quick Read

  • VIOV has the higher backtested relative Sharpe (1.082 vs 0.948).
  • VTWV has the lower published fee (0.06% vs 0.10%).
  • VIOV is cheaper on dividend valuation (99 vs 113, where 100 is each fund's historical median).

These are screening signals, not a complete review of portfolio construction, turnover, taxes, or trading quality.

VIOV

Vanguard S&P Small-Cap 600 Value ETF
SMB HML
Adj. R2
0.979
Rel. Sharpe
1.082
Mkt beta
0.99
AUM
US$1.6B
MER
0.10%
Valuation
99

VTWV

Vanguard Russell 2000 Value ETF
SMB HML
Adj. R2
0.980
Rel. Sharpe
0.948
Mkt beta
0.98
AUM
US$1.1B
MER
0.06%
Valuation
113

Factor Exposure Match

Blue bars compare raw factor beta magnitude. Green bars compare absolute t-stat strength. Dim bars indicate the t-stat is below 1.96.

SMB
VIOV
+0.90
|t|
+32.1
VTWV
+0.83
|t|
+31.6
diff +0.07
HML
VIOV
+0.35
|t|
+13.0
VTWV
+0.37
|t|
+14.5
diff -0.02
RMW
VIOV
+0.10
|t|
+3.2
VTWV
+0.02
|t|
+0.6
diff +0.08
CMA
VIOV
+0.05
|t|
+1.4
VTWV
+0.01
|t|
+0.2
diff +0.05
UMD
VIOV
-0.04
|t|
-1.9
VTWV
-0.00
|t|
-0.2
diff -0.04

Why This Pair Matches

Exposure level
90
Exposure shape
100
Mkt beta diff
0.01
Rel. Sharpe diff
0.134

This comparison focuses on measured factor exposure. It does not compare holdings methodology, turnover, tax handling, or issuer process. Backtested relative Sharpe is a secondary signal rather than a stand-alone forecast. See methodology.

VIOV fund page VTWV fund page US ETF Leaders US Universe
Important context

VerifiedBeta publishes educational ETF research, not personalized investment advice, portfolio management, or security recommendations. Funds that screen well here can still be unsuitable for your objectives, taxes, liquidity needs, or constraints. Review fund documents, methodology assumptions, and your own circumstances before acting. See the full disclaimer.